Last updated: February 23, 2026
What Is NDC 00955-1052?
NDC 00955-1052 is a drug marketed as Fluticasone Propionate Nasal Spray, 50 mcg per spray. The drug is indicated for allergic rhinitis and nasal polyps management.
Market Size and Demand
Current Market Environment
- The global allergic rhinitis market is valued at approximately $6.7 billion as of 2022.
- The nasal corticosteroids segment, including Fluticasone Propionate, accounts for around 65% of this market.
- The U.S. remains the largest market, with sales exceeding $2 billion annually for nasal corticosteroids.
Key Market Drivers
- Increased prevalence of allergic rhinitis—an estimated 10-30% of the global population.
- Growing awareness and diagnosis rates.
- Preference for intranasal formulations due to fewer systemic side effects.
Competitive Landscape
Major competitors include:
- Fluticasone Propionate (e.g., Flonase)
- Budesonide (Rhinocort)
- Mometasone (Nasonex)
Market share for Fluticasone-based products exceeds 50% in the nasal corticosteroids segment.
Regulatory Status and Patent Landscape
- Fluticasone Propionate Nasal Spray is approved by the FDA; patent protection expired in 2021.
- Generics entered the market post-patent expiry, intensifying price competition.
- No new formulation approvals specific to NDC 00955-1052 are pending or expected.
Pricing Analysis
Current Pricing Trends
- Brand-name products: $30-$40 per 120-dose container.
- Generic products: $15-$25 per 120-dose container.
- Average wholesale price (AWP): approximately $0.25 per spray for generics, and $0.30 for branded.
Price Trends and Projections
| Year |
Estimated Average Price per Spray |
Notes |
| 2022 |
$0.30 |
Market dominated by generics |
| 2023 |
$0.28 – $0.32 |
Slight decrease due to increased generic competition |
| 2024 |
$0.27 – $0.30 |
Price stabilization expected |
| 2025 |
$0.25 – $0.28 |
Further declines as more generics enter the market |
Influencing Factors
- Patent expiration in 2021 opened the market for generics, leading to price erosion.
- Potential shortages or manufacturing disruptions could influence prices temporarily.
- Insurance coverage policies impact out-of-pocket costs, indirectly affecting demand and pricing.
Future Market and Price Dynamics
- The nasal corticosteroids market is expected to grow at a compound annual growth rate (CAGR) of 3-4% through 2027.
- Price pressure from generics will likely sustain a downward trend.
- Uptake of biosimilars or new delivery mechanisms (e.g., metered nasal spray devices) could influence future pricing.
Financial Outlook
- The total U.S. market for nasal corticosteroid sprays will reach approximately $2.5 billion in 2023.
- NDC 00955-1052, being a generic formulation, will see prices converge toward $0.25 per spray.
- Revenue estimates for a typical 120-dose container: $30–$36 retail, depending on distribution channel and insurance.
Conclusions
- NDC 00955-1052 operates within a mature, highly competitive market.
- Price erosion is ongoing, driven by generic entry.
- Market growth remains steady, supported by disease prevalence rather than new product innovations.
Key Takeaways
- Post-expiry of patent protection, prices for Fluticasone Propionate Nasal Spray have declined significantly.
- Generics dominate the market, with prices averaging around $0.25 per spray.
- Market growth continues at 3-4%, sustained by increasing prevalence of allergic rhinitis.
- Competition from new delivery methods or biosimilars could influence the market landscape.
- Future price stabilization is likely around current generic levels unless supply disruptions occur.
FAQs
1. What is the typical price range for Fluticasone Propionate Nasal Spray?
Between $15 and $40 for a 120-dose container, with generics averaging $15–$25.
2. How does patent expiry affect prices?
Patent expiry opens the market to generics, causing prices to drop by 30–50%.
3. Are there any upcoming regulatory changes affecting this drug?
No current or announced regulatory changes specific to NDC 00955-1052.
4. What factors could alter future prices?
Supply disruptions, new formulations, insurance reimbursement policies, or regulatory decisions.
5. What is the growth outlook for this market segment?
A CAGR of 3–4% through 2027, driven by increasing allergy prevalence.
References
- Market Research Future. (2022). Global Allergic Rhinitis Market Analysis.
- IQVIA. (2022). Pharmaceutical Market Data Reports.
- FDA. (2021). Patent and Exclusivity Information for Fluticasone Propionate.
- Retail Pharmacy Pricing Data. (2023). Average Wholesale Price Reports.
- Grand View Research. (2023). Nasal Corticosteroids Market Size and Forecast.
